Get the Stockscreener App
29.22
0.24%
-0.07
After Hours:
28.74
-0.48
-1.64%
Harmony Biosciences Holdings Inc stock is traded at $29.22, with a volume of 549.86K.
It is down -0.24% in the last 24 hours and up +5.83% over the past month.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
See More
Previous Close:
$29.29
Open:
$29.46
24h Volume:
549.86K
Relative Volume:
0.65
Market Cap:
$1.69B
Revenue:
$868.45M
Net Income/Loss:
$158.69M
P/E Ratio:
10.79
EPS:
2.7087
Net Cash Flow:
$328.64M
1W Performance:
+2.63%
1M Performance:
+5.83%
6M Performance:
+9.73%
1Y Performance:
+1.63%
1-Day Range:
$29.19
$29.88
1-Week Range:
$28.09
$29.88
52-Week Range:
$25.52
$40.87
Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile
Name
Harmony Biosciences Holdings Inc
Sector
Industry
Phone
(484) 539-9800
Address
630 W GERMANTOWN PIKE, PLYMOUTH MEETING
Compare HRMY vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HRMY
Harmony Biosciences Holdings Inc
|
29.22 | 1.69B | 868.45M | 158.69M | 328.64M | 2.7087 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-23-26 | Downgrade | Deutsche Bank | Buy → Hold |
| Feb-23-26 | Downgrade | Truist | Buy → Hold |
| Feb-11-26 | Resumed | UBS | Neutral |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-10-25 | Resumed | Goldman | Neutral |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Dec-17-24 | Initiated | H.C. Wainwright | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Sep-10-24 | Initiated | UBS | Buy |
| Jun-21-24 | Initiated | Citigroup | Buy |
| Jan-02-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-25-23 | Downgrade | Goldman | Neutral → Sell |
| Sep-07-23 | Initiated | Berenberg | Buy |
| Apr-20-23 | Initiated | BofA Securities | Neutral |
| Oct-14-22 | Upgrade | Janney | Neutral → Buy |
| Oct-14-22 | Upgrade | Jefferies | Hold → Buy |
| Aug-03-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Downgrade | Goldman | Buy → Neutral |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Apr-14-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-01-21 | Initiated | Oppenheimer | Outperform |
| Nov-04-21 | Initiated | Raymond James | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Mar-29-21 | Upgrade | Goldman | Neutral → Buy |
| Sep-14-20 | Initiated | Goldman | Neutral |
| Sep-14-20 | Initiated | Jefferies | Buy |
| Sep-14-20 | Initiated | Piper Sandler | Overweight |
View All
Harmony Biosciences Holdings Inc Stock (HRMY) Latest News
Harmony Biosciences names Glenn Reicin as CFO - Investing.com
Harmony Biosciences to present at Needham Healthcare Conference - MSN
AQR Small Cap Multi-Style Fund's Harmony Biosciences Holdings Inc(HRMY) Holding History - GuruFocus
Harmony Biosciences Appoints New CFO - National Today
Harmony (HRMY) Maintains 2026 Revenue Projections of Up to $1.04 Billion - GuruFocus
Harmony Biosciences Names Glenn Reicin Finance Chief as Sandip Kapadia Departs - Moomoo
Harmony Biosciences Holdings, Inc. Reiterates Revenue Guidance for the Year 2026 - marketscreener.com
Harmony Biosciences Holdings, Inc. Announces Chief Financial Officer Changes - marketscreener.com
Harmony Biosciences Names New CFO to Drive Growth - TipRanks
Harmony Biosciences names Glenn Reicin as CFO By Investing.com - Investing.com India
Harmony Biosciences Holdings, Inc. (HRMY) Stock Price, News, Quote & History - Yahoo Finance
Harmony Biosciences Holdings, Inc. (HRMY) Latest Stock News & Headlines - Yahoo Finance
Harmony Biosciences Names Glenn Reicin CFO, Reaffirms $1B+ Wakix Revenue Target - citybiz
New Harmony Biosciences (NASDAQ: HRMY) CFO as 2026 WAKIX revenue view held - Stock Titan
Harmony Biosciences Appoints Glenn Reicin as Chief Financial Officer - Bluefield Daily Telegraph
New CFO arrives as Harmony sticks to $1B-plus 2026 sales target - Stock Titan
Harmony Biosciences Eyes $1B WAKIX Runway, Teases 2026 Pipeline Catalysts at Needham Conference - Yahoo Finance
Exit Recap: Is Harmony Biosciences Holdings Inc impacted by rising rates2026 Reactions & Low Drawdown Trading Strategies - baoquankhu1.vn
Harmony Biosciences appoints COO, updates board membership - MSN
Will Harmony’s New COO and Board Reboot Change Harmony Biosciences Holdings' (HRMY) Narrative? - simplywall.st
Analyst Upgrade: Can Harmony Biosciences Holdings Inc lead its sector in growthWeekly Earnings Recap & Weekly Market Pulse Updates - baoquankhu1.vn
Harmony Biosciences Raises Full-Year Revenue Guidance Ahead Of Earnings: Why Are Wakix Franchise Numbers Crucial? - MSN
Harmony Biosciences Appoints COO, Updates Board Membership - MyChesCo
Harmony Biosciences to Present at Needham Healthcare Conference - MyChesCo
(HRMY) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Can Harmony Biosciences Holdings Inc reach all time highs this yearRate Hike & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Harmony Biosciences (HRMY) CCO RSUs Vest; 3,173 Shares Withheld for Taxes - Stock Titan
HRMY SEC FilingsHarmony Biosciences Holdings, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Harmony Biosciences Holdings, I (HRMY) Stock forecasts - Yahoo Finance UK
Peter Anastasiou At Harmony Biosciences Hldgs Exercises Options Worth $0 - Benzinga
Harmony Biosciences (HRMY) awards 212,241 stock options to COO Anastasiou - Stock Titan
Harmony Biosciences (HRMY) director granted 17,710 stock options at $27.74 strike - Stock Titan
Harmony Biosciences (HRMY) director Troy Ignelzi files initial Form 3 - Stock Titan
Harmony Biosciences Holdings, Inc. (HRMY) stock price, news, quote and history - uk.finance.yahoo.com
Harmony Biosciences Holdings, Inc. ($HRMY) CEO 2025 Pay Revealed - Quiver Quantitative
Harmony Biosciences Holdings (HRMY) Valuation After New COO And Board Appointments - Yahoo Finance
Harmony Biosciences Appoints Peter Anastasiou as Chief Operating Officer - The Globe and Mail
[ARS] Harmony Biosciences Holdings, Inc. SEC Filing - Stock Titan
Executive pay and board elections at Harmony Biosciences (HRMY) 2026 virtual meeting - Stock Titan
A Look At Harmony Biosciences Holdings (HRMY) Valuation After Recent Share Price Weakness - Sahm
Harmony Biosciences names Peter Anastasiou as chief operating officer By Investing.com - Investing.com India
Harmony Biosciences Holdings Inc Stock (HRMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):